Bio - Neuroscience 2024 | Broadreach Global | 13 February 2024 | Rosarium, Amstelpark 1, Europaboulevard, 1083 HZ Amsterdam, Netherlands

Insight - Innovation - Access - Engagement - Partnering

The global partnering and investment summit for global leaders and innovators in CNS neuroscience and psychiatric drug discovery, development, platforms and technologies.

Convened by-invitation, It is a high level, boutique gathering of key thought leaders, innovators and decision-makers from all key stakeholder groups crucial to the discovery, development and market launch of novel therapeutics and breakthrough platforms and technologies.

High level access, serious, sustained engagement, discussion and networking with key stakeholders. Sharing models, lessons learned, solutions, ways forward and best practices. A truly curated and unique summit to facilitate business and accelerate innovation.

Who's Coming?
Two days of sustained, interactive discussion, networking and partnering with:

• Industry Leaders
Senior industry leaders from pharma, large biotech and healthcare companies. Heads of therapeutic area, R&D, clinical development, biological sciences, M&A, scouting, business development & licensing.
• Key Opinion Leaders
Key Opinion Leaders from all stakeholder groups crucial to the successful development, approval and market launch of novel CNS neuroscience and psychiatric therapeutics, platforms and technologies.
• Founders & CEOs
From startup and growth companies at the cutting edge of the future of CNS neuroscience and psychiatric drug discovery, development, advanced therapies, platforms and technologies.
• Government & NGOs
Public agencies, funding bodies, foundations, societies, associations, patient organizations & NGOs in CNS neurosciences and psychiatry.
• Investors
In CNS neuroscience and psychiatric drug development, platforms and technologies.
VC and corporate venture, private equity, family offices, angels & HNW.
• Leading Advisors
A selected group of leading specialized advisors and consultants with deep subject matter expertise relevant to participants.

2024 Speakers

ADVISORY BOARDS:

Stacie Weninger
Executive Director, F-Prime Biomedical Research Initiative

David Reynolds
Venture Partner, SV Health Investors, CEO, LoQus23 Therapeutics

Sourav Kole
Managing Director, Dolby Family Ventures

Joachim Scholpp
Global Head Translational Medicine CNS & Emerging Areas, Boehringer Ingelheim

Kalpana Merchant, PhD
Chief Scientific Officer, Retromer Therapeutics

Juan Carlos Lopez
Managing Director, Research Grants, RTW Charitable Foundation

Mark Treherne
Commercial Scientist, Entrepreneur & Investor, Chairperson, Monument Therapeutics, Talisman Therapeutics, Ubiqent, NuVision Biotherapies

Pieter van Bokhoven
Chief Scientific Officer, Amsterdam Neuroscience IAO, VUMC

Andrea Soto Padilla
Business Development, Amsterdam UMC

Pawel Świeboda
Founder, NeuroCentury; Practice Lead Neurotechnology, ICFG; Senior Advisor on Brain Health, FIPRA.

Hakan Goker
Managing Director, Head of Healthcare & Life Sciences, M-Ventures

Christian J. Suojanen
Founder & CEO - Broadreach Global

SPEAKERS:

Florian Brand
CEO & Co-Founder, Atai Life Sciences

Mary Chamberlain-Tharp
Chief Business Officer, Neumora

Philip Scheltens
Head of the Dementia Fund, Partner - EQT Life Sciences, Professor of Neurology, Amsterdam University Medical Center

Olga Krylova
Director Of Business Development & Innovation, Otsuka Pharmaceutical Companies Europe

Christian Thomsen
Global Head of CNS BD&L, Boehringer Ingelheim

Raúl Martín-Ruiz
Partner, Ysios Capital

Claire Leurent
Managing Director, Abbvie Ventures

Cillian King
Managing Director, EQT Life Sciences

Jasper Bos
General Partner, Forbion

Martien Kas
President, European College of NeuroPsychopharmacology (ECNP), Professor of Behavioral Neuroscience, Groningen Institute for Evolutionary Life Sciences, University of Groningen

Dee Datta
CEO, Switch Therapeutics

Niels Plath
Chief Scientific Officer, Muna Therapeutics

José Luis Lanciego
Chair, International Brain Research Organization Pan-European Committee, Head, Laboratory of Functional Neuroanatomy of the Basal Ganglia, CNS Gene Therapy Program, CIMA, University of Navarra

Kees Been
Chief Executive Officer, Kynexis Therapeutics, Inc

Aaron Koenig
Chief Medical Officer, Delix Therapeutics

Craig Thompson
Chief Executive Officer, Cerevance

Maria Luisa Pineda
CEO & Co-Founder, Envisagenics

Jim Sullivan
Co-Founder & CEO, Vanqua Bio

Yael Weiss
CEO, Mahzi Therapeutics

Frédéric Destrebecq
Executive Director, European Brain Council

Terry Pirovolakis
Founder & CEO, Elpida Therapeutics

Anela Vukoja
COO, Apollo Health Ventures

Carlos Buesa
Founder & Chairman of the Board, Oryzon

John Kastelein
CSO, New Amsterdam Pharma, Operating Partner, Forbion

Anta Gkelou
Principal, Sofinnova Partners

Jason Dichtenberg
CEO, SpliceRNA, Advisory Board Member, Alzheimers Drug Discovery Foundation, New York

Arno de Wilde
Director, EQT Life Sciences

Rowan Gardner
Co-founder and Chief Business & Investment Officer, PrecisionLife

Hilgo Bruining
Professor, Neurobiological developmental disorders, Amsterdam UMC. Head, NYou Neurodevelopmental Precision Center

Delphine Charvin
Operating Partner, Argobio Studio

2024 Sponsors

GOLD SPONSOR:
• Warman O'Brien

SILVER SPONSOR:
• Julius Clinical